Stock 688046 GEMPHARMATECH CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings GemPharmatech Co., Ltd.

Equities

688046

CNE100005964

End-of-day quote Shanghai S.E.
Other stock markets
 06:00:00 2024-06-06 pm EDT 		5-day change 1st Jan Change
11.61 CNY +1.75% Intraday chart for GemPharmatech Co., Ltd. -0.34% -42.38%
Apr. 26 GemPharmatech Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Apr. 03 Tranche Update on GemPharmatech Co., Ltd.'s Equity Buyback Plan announced on December 27, 2023. CI

Summary

  • From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

  • According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
  • The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
  • Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • Consensus analysts have strongly revised their opinion of the company over the past 12 months.

Weaknesses

  • The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
  • The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
  • The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
  • The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

1st Jan change Capi. Investor Rating ESG Refinitiv
GEMPHARMATECH CO., LTD. Stock GemPharmatech Co., Ltd.
-42.38% 657M -
MODERNA, INC. Stock Moderna, Inc.
+51.85% 57.87B
B-
LONZA GROUP AG Stock Lonza Group AG
+41.42% 40.25B
A
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-5.25% 39.94B
B
CELLTRION, INC. Stock Celltrion, Inc.
-5.16% 28.54B
C
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+12.79% 26.4B
B-
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-20.18% 19.33B
B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+30.88% 12.4B
C+
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+0.61% 12.23B
B+
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+25.06% 12.2B
B+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-

Valuation

P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
-
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
  1. Stock Market
  2. Equities
  3. 688046 Stock
  4. Ratings GemPharmatech Co., Ltd.